Rabbit Recombinant Monoclonal GLP-1 antibody. Suitable for WB, IHC-P and reacts with Recombinant fragment, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | IHC-P | ICC/IF | Flow Cyt | |
---|---|---|---|---|
Human | Expected | Tested | Not recommended | Not recommended |
Recombinant fragment | Tested | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment | Dilution info 1/5000 | Notes For unpurified, use 1/2000. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes Antigen retrieval is recommended. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Recombinant fragment | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Recombinant fragment | Dilution info - | Notes - |
Select an associated product type
Glucagon. Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon-like peptide 1. Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable). Glucagon-like peptide 2. Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin. Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin. May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
Pro-glucagon, GCG
Rabbit Recombinant Monoclonal GLP-1 antibody. Suitable for WB, IHC-P and reacts with Recombinant fragment, Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Glucagon also known as the “hunger hormone" is a 29-amino acid peptide hormone with a mass of approximately 3.5 kDa. It plays an important role in glucose metabolism and regulation of blood sugar levels. The human pancreas specifically the alpha cells located in the islets of Langerhans synthesizes and secretes glucagon. This hormone binds to glucagon receptors which are widely expressed across tissues including the liver and kidney where it initiates a cascade of signaling events.
Glucagon plays a central role in maintaining glucose homeostasis. It increases blood glucose by promoting gluconeogenesis and glycogenolysis in the liver. Though glucagon mainly acts independently it exhibits significant interactions with other metabolic hormones such as insulin. This interaction helps balance blood sugar levels as glucagon and insulin work in opposition to ensure optimal blood glucose regulation.
Glucagon primarily impacts the cAMP signaling pathway significantly increasing intracellular cAMP levels. This pathway initiates a complex series of downstream events including increased enzyme activity for gluconeogenesis and glycogen breakdown in the liver. Glucagon also cross-talks with insulin signaling pathways enabling the intertwined regulation of metabolism through these hormones and maintaining glucose balance.
Glucagon is closely linked to diabetes and hyperglycemia. Individuals with diabetes often exhibit dysregulated glucagon secretion leading to unstable blood sugar levels. Glucagon interacts with insulin in the pathology of diabetes where an improper balance between these hormones can exacerbate the disease. The understanding of glucagon's role in these conditions makes it a target for new therapeutic strategies including recombinant glucagon treatments and assays.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemical staining of paraffin embedded human pancreas with purified ab108426 at a working dilution of 1/250. The secondary antibody used is HRP goat anti-rabbit IgG H&L (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
Unpurified ab108426, at 1/100 dilution, staining Glucagon in paraffin-embedded Human pancreas tissue by Immunohistochemistry.
All lanes: Western blot - Anti-Glucagon antibody [EPR3070-45] (ab108426) at 1/2000 dilution
All lanes: Glucagon recombinant protein at 10 µg
Predicted band size: 21 kDa
Unpurified ab108426 showing negative staining in Skeletal muscle tissue.
Unpurified ab108426 showing negative staining in Normal lung tissue.
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Unpurified ab108426 showing negative staining in Normal kidney tissue.
Unpurified ab108426 showing negative staining in Normal brain tissue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com